Shaperon Inc.

Shaperon Inc. develops therapies based on its GPCR19-inflammasome inhibitor and NanoMab antibody platforms for immune diseases. Its pipeline includes NuGel for atopic dermatitis (Phase 2), NuDifin for wound inflammation and tissue regeneration, NuRalin for atopic dermatitis, and NuAreatin for alopecia areata. The company also offers NuCerin for neuroinflammation, NuSepin for systemic inflammation, and NuPulin for inflammation-driven pulmonary fibrosis. Additional candidates include Papiliximab (a NanoMab-based bispecific antibody blocking PD-L1 and CD47 for leukemia), Ovizumab (tumor-specific immunotherapy), Regtizumab (anti-tumor immunity), and Rbody (a NanoMab format enabling LNP-mRNA therapeutics). It also provides RumiLua, a cosmeceutical ingredient. Founded in 2008, Shaperon is headquartered in Seoul, South Korea.